槐耳颗粒联合吡柔比星介入治疗乙型肝炎肝癌患者的临床疗效

目的:观察槐耳颗粒联合吡柔比星介入治疗乙型肝炎病毒(HBV)DNA阴性的乙肝肝癌患者的临床疗效并记录其不良反应。方法:选取2012年2月至2016年2月(随访时间为1年)在中国医科大学附属第一医院肝胆外科住院符合临床研究标准的HBV DNA阴性的肝癌患者120例(完成临床研究且临床资料数据可靠的96例),随机分为干预组与对照组,每组60例。对照组给予介入治疗(盐酸吡柔比星+超液化碘油)+替恩卡韦(抗病毒治疗)+常规保肝治疗;干预组在对照组的基础上给予槐耳颗粒治疗,2组均连续治疗6个月。治疗后比较2组的临床疗效、HBV DNA定量、肝酶、免疫学指标。结果:治疗后干预组近期及远期临床疗效均优于对照组(P0.05),治疗前2组的肝酶、HBV DNA定量、免疫学指标差异无统计学意义(P0.05),治疗后2组的肝酶、HBV DNA定量较治疗前有所降低(P0.05),且干预组低于对照组(P0.05),治疗后2组的免疫学(细胞免疫、体液免疫)指标均优于治疗前(P0.05),且干预组优于对照组(P0.05)。2组治疗中均出现白细胞降低、血小板计数降低、恶心、呕吐等不良反应。结论:槐耳颗粒联合介入治疗能很好的提高乙肝肝癌的临床疗效,且不良反应少。

Clinical Efficacy Analysis of Huaier Granule Combined with Interventional Treatment on Patients with HBV DNA-negative Hepatitis B

To observe the clinical efficacy of Huaier granule combined with interventional treatment on patients with HBV DNA-negative Hepatitis B and record the adverse reaction. Methods:A total of 120 liver cancer patients with HBV DNA-negative Hepatitis B were randomly divided into intervene group and control group, with 60 patients in each group. Control group received intervention, percutaneous puncture of femoral artery, then injected Pirarubicin hydrochloride for injection + lipiodol in parent artery until blood stagnation + antivirus (entecavir), and also conventional liver protection therapy was conducted; intervene group additionally received Huaier granule for continuous 6 months. Clinical efficacy, HBV DNA quantification, and liver function indexes in the two groups were compared. Results:After treatment, short and long-term clinical efficacy in observation group was significantly better than the control group (P<0.05). Before the treatment, there were no significant differences in HBV DNA quantification and liver function (P>0.05). After treatment, the HBV DNA quantification and liver function were both lower than before treatment in both groups (P<0.05), and the HBV DNA quantification and liver function were lower in the intervene group than control group (P<0.05). After treatment, the cell-mediated immunity and humoral immunity were both better than before treatment in both groups (P<0.05), and the cell-mediated immunity and humoral immunity were better in the intervene group than control group (P<0.05). During the treatment, reducing leucocyte and platelet, nausea, vomit, etc. were occuring in both groups. Conclusion:Huaier granule combined with interventional treatment on patients with HBV DNA-negative Hepatitis B can improve the clinical efficacy, with less side effects.